An observational study for incidence of thromboembolism in lung cancer patients, and the evaluation for efficacy and safety of edoxaban in active cancer patients with venous thromboembolism
Phase of Trial: Phase IV
Latest Information Update: 21 Jun 2016
At a glance
- Drugs Edoxaban (Primary)
- Indications Non-small cell lung cancer; Small cell lung cancer
- Focus Therapeutic Use
- 19 Jun 2016 Planned End Date changed from 31 Mar 2021 to 31 May 2021.
- 19 Jun 2016 Status changed from not yet recruiting to recruiting.
- 24 May 2016 New trial record